Biontech outlines Euro2B-Euro2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition
Source: SeekingAlpha
2026-03-10 17:40:59 ET
More on BioNTech
- BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
- BioNTech: The Market Is Pricing Low Oncology Success
- BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- BioNTech falls on outlook, departure of co-founders
- BioNTech Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Biontech outlines €2B–€2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition
BioNTech SE
NASDAQ: BNTX
BNTX Trading
-20.41% G/L:
$80.30 Last:
8,115,591 Volume:
$82.81 Open:
BNTX Latest News
BNTX Stock Data
$26,377,590,776
95,508,380
N/A
104
N/A
Biotechnology & Life Sciences
Healthcare
DE
Mainz
